发布求助
文献互助 智能选刊 最新文献

Future medicinal chemistry最新文献

筛选
英文 中文
Synthesis and antimicrobial activity evaluation of pyrazole derivatives containing imidazothiadiazole moiety. 含咪唑噻二唑类吡唑衍生物的合成及抗菌活性评价。
IF 3.2 4区 医学
Future medicinal chemistry Pub Date : 2025-01-01 Epub Date: 2024-12-26 DOI: 10.1080/17568919.2024.2444868
Lan-Ying Han, Jing-Xin Sun, Chuang Liu, Bing Ai, Ming-Guan Piao, Changhao Zhang, Ji-Shan Quan, Cheng-Hua Jin
{"title":"Synthesis and antimicrobial activity evaluation of pyrazole derivatives containing imidazothiadiazole moiety.","authors":"Lan-Ying Han, Jing-Xin Sun, Chuang Liu, Bing Ai, Ming-Guan Piao, Changhao Zhang, Ji-Shan Quan, Cheng-Hua Jin","doi":"10.1080/17568919.2024.2444868","DOIUrl":"10.1080/17568919.2024.2444868","url":null,"abstract":"<p><strong>Aim: </strong>The purpose of this work was to investigate the antimicrobial activity of pyrazole derivatives (21a - i and 23a - o) synthesized.</p><p><strong>Materials & methods: </strong>The pyrazole derivatives were synthesized, molecular docked and tested for their antimicrobial activity, cytotoxicity, and hemolysis rate.</p><p><strong>Results: </strong>Most of the target compounds showed high selective inhibitory activity against multi-drug resistance compared with other strains. Of these, compounds 21c (MIC = 0.25 µg/mL) and 23 h (MIC = 0.25 µg/mL) showed the strongest antibacterial activity, which was 4-flods than that of the positive control compound gatifloxacin (MIC = 1 µg/mL). Furthermore, compound 23 h showed no cytotoxicity to human LO2 cells, and did not show hemolysis even at ultra-high concentration.</p><p><strong>Conclusion: </strong>These results prompted that these compounds are valuable for further development as antimicrobial agents.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"157-170"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11749441/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive drug-like assessment of pyridine carbothioamide analogs: from molecular modeling to in-vivo evaluation. 吡啶碳硫酰胺类似物的综合药物样评价：从分子建模到体内评价。
IF 3.2 4区 医学
Future medicinal chemistry Pub Date : 2025-01-01 DOI: 10.1080/17568919.2024.2444864
Sana Ali, Asia Naz Awan, Sehrish Batool, Shazmeen Aslam, Ayesha Naseer
{"title":"Comprehensive drug-like assessment of pyridine carbothioamide analogs: from molecular modeling to <i>in-vivo</i> evaluation.","authors":"Sana Ali, Asia Naz Awan, Sehrish Batool, Shazmeen Aslam, Ayesha Naseer","doi":"10.1080/17568919.2024.2444864","DOIUrl":"10.1080/17568919.2024.2444864","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the anti-inflammatory potential of novel class of chemical compounds designed by the linkage of carbothioamide moiety with pyridine.</p><p><strong>Materials & methods: </strong>In silico analysis was conducted using molecular docking followed by an in vitro cytotoxicity assay and evaluation of anti-inflammatory activity. Subsequently, in vivo performance was determined using the Complete Freund's Adjuvant-induced inflammatory model, employing macroscopic, histopathological, and protein expression analyses.</p><p><strong>Results: </strong>Molecular interaction studies revealed that compound R2 displayed the most favorable binding mode with human nitric oxide synthase, cyclooxygenase-1, and cycloxygenase-2. All compounds exhibit dose-dependent cytotoxicity. Notably, compound R4 was safer at higher concentration, whereas compound R2 was comparatively toxic. The in vitro anti-inflammatory activity demonstrated half maximal inhibitory concentration (IC<sub>50</sub>) values ranging from 10.25 ± 0.0 to 23.15 ± 4.24 µM, with compound R6 exhibiting the lowest IC<sub>50</sub> value and compound R3 showing the highest. The in vivo results corroborated the anti-inflammatory effects, with a significant reduction in paw size (<i>p</i> < 0.001). Among the tested compounds, compound R4 exhibited the most potent anti-inflammatory activity, whereas R2 exhibited the least potency.</p><p><strong>Conclusion: </strong>The study highlights the promise of discovering new anti-inflammatory drugs containing pyridine moiety with proven potency, efficacy, and reduced side effects.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"171-181"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11749381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142913916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel inhibitors of PARP1 and PARP14: design, synthesis, and potentiation of cisplatin efficacy in cancer. 新型PARP1和PARP14抑制剂：设计、合成和增强顺铂在癌症中的疗效。
IF 3.2 4区 医学
Future medicinal chemistry Pub Date : 2025-01-01 Epub Date: 2024-12-18 DOI: 10.1080/17568919.2024.2437972
Caleb M T Kam, Amanda L Tauber, Matthew S Zunk, Catherine M McDermott, Stephan M Levonis, Stephanie S Schweiker
{"title":"Novel inhibitors of PARP1 and PARP14: design, synthesis, and potentiation of cisplatin efficacy in cancer.","authors":"Caleb M T Kam, Amanda L Tauber, Matthew S Zunk, Catherine M McDermott, Stephan M Levonis, Stephanie S Schweiker","doi":"10.1080/17568919.2024.2437972","DOIUrl":"10.1080/17568919.2024.2437972","url":null,"abstract":"<p><strong>Background: </strong>Poly(ADP-ribose) polymerase (PARP) is a superfamily of enzymes involved in cell survival. Both PARP1 and PARP14 are overexpressed in malignancies. No clinically approved PARP14 inhibitors are available, and PARP1 inhibitors are generally nonspecific, resulting in a need for a more diverse library of selective PARP1 and PARP14 inhibitors.</p><p><strong>Materials and methods: </strong>Based on the previous lead compounds <b>1</b> and <b>2</b>, 26 novel compounds were designed, synthesized, and screened against PARP1 and PARP14. Compounds with the best in vitro inhibitory results were further screened against PARP2, PARP3, PARP5a, PARP7, and PARP15.</p><p><strong>Results and conclusion: </strong>The 26 novel compounds demonstrated a lesser inhibitory effect than the lead compounds. Compounds <b>1</b> and <b>2</b> were further investigated using in vitro cell viability assays, which revealed that cells treated with either lead PARP inhibitor and cisplatin in combination had significantly lower survival rates than those treated with cisplatin alone. At 10 µM, the combination showed more significant cell survival reduction, suggesting greater inhibition of PARP increases lethality, particularly in HeLa and PC-3 cell lines at 96 h and beyond.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"35-58"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel isatin conjugates endowed with analgesic and anti-inflammatory properties: design, synthesis and biological evaluation. 具有镇痛和抗炎特性的新型靛红共轭物：设计、合成和生物学评价。
IF 3.2 4区 医学
Future medicinal chemistry Pub Date : 2025-01-01 Epub Date: 2024-12-16 DOI: 10.1080/17568919.2024.2437981
LaVauria D Brown, Adel S Girgis, Shruti Patel, Nermin Samir, Mona F Said, Anurag T K Baidya, Rajnish Kumar, Jade Moore, Anshuman Khadanga, Rajeev Sakhuja, Siva S Panda
{"title":"Novel isatin conjugates endowed with analgesic and anti-inflammatory properties: design, synthesis and biological evaluation.","authors":"LaVauria D Brown, Adel S Girgis, Shruti Patel, Nermin Samir, Mona F Said, Anurag T K Baidya, Rajnish Kumar, Jade Moore, Anshuman Khadanga, Rajeev Sakhuja, Siva S Panda","doi":"10.1080/17568919.2024.2437981","DOIUrl":"10.1080/17568919.2024.2437981","url":null,"abstract":"<p><strong>Aims: </strong>This study aimed to develop novel molecular hybrid conjugates integrating isatin, rhodanine, and phthalimide pharmacophores to create effective analgesic and anti-inflammatory agents with improved safety profiles over existing treatments.</p><p><strong>Materials & methods: </strong>A series of hybrid conjugates (<b>4a - l</b>) were synthesized and evaluated through in vitro and in vivo biological assays. The most promising compound, <b>4c</b>, underwent extensive pharmacological and toxicological evaluations. Molecular docking, molecular dynamics simulations, and 2D-QSAR studies were performed to elucidate the mechanism of action and validate the experimental findings.</p><p><strong>Results: </strong>Compound <b>4c</b> exhibited potent analgesic and anti-inflammatory activity, effectively inhibiting COX-2 and pro-inflammatory cytokines (IL-6 and TNF-α). Its superior selectivity index (SI) was 1.11 compared to 0.67 for indomethacin. It demonstrated an ulcer index of 2.9 versus 10.23 for indomethacin, indicating reduced gastrointestinal toxicity. Molecular docking simulations revealed a strong binding affinity with COX-2 (-9.832 kcal/mol), and molecular dynamics confirmed the stability of the COX-2 complex.</p><p><strong>Conclusions: </strong>Compound <b>4c</b> emerged as a promising lead candidate for developing safer and more effective anti-inflammatory and analgesic agents. Its robust efficacy, safety profile, and computational validation highlight its potential for further optimization in therapeutic applications.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"59-73"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The design and development of LRRK2 inhibitors as novel therapeutics for Parkinson's disease. LRRK2抑制剂作为帕金森病新疗法的设计和开发。
IF 3.2 4区 医学
Future medicinal chemistry Pub Date : 2025-01-01 Epub Date: 2024-12-24 DOI: 10.1080/17568919.2024.2444875
Xiaoxue Bai, Jiawei Zhu, Yao Chen, Haopeng Sun
{"title":"The design and development of LRRK2 inhibitors as novel therapeutics for Parkinson's disease.","authors":"Xiaoxue Bai, Jiawei Zhu, Yao Chen, Haopeng Sun","doi":"10.1080/17568919.2024.2444875","DOIUrl":"10.1080/17568919.2024.2444875","url":null,"abstract":"<p><p>Parkinson's disease (PD) is a common neurodegenerative disease affecting nearly 10 million people worldwide and placing a heavy medical burden on both society and families. However, due to the complexity of its pathological mechanisms, current treatments for PD can only alleviate patients' symptoms. Therefore, novel therapeutic strategies are urgently sought in clinical practice. Leucine-rich repeat kinase 2 (LRRK2) has emerged as a highly promising target for PD therapy. Missense mutations within the structural domain of LRRK2, the most common genetic risk factor for PD, lead to abnormally elevated kinase activity and increase the risk of developing PD. In this article, we provide a comprehensive overview of the structure, biological function, and pathogenic mutations of LRRK2, and examine recent advances in the development of LRRK2 inhibitors. We hope that this article will provide a reference for the design of novel LRRK2 inhibitors based on summarizing the facts and elucidating the viewpoints.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"221-236"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11749465/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SETDB1: an emerging target for anticancer drug development. SETDB1：抗癌药物开发的新靶点。
IF 3.2 4区 医学
Future medicinal chemistry Pub Date : 2025-01-01 Epub Date: 2024-12-25 DOI: 10.1080/17568919.2024.2444869
Gustavo Henrique Goulart Trossini, Haifa Hassanie, André Berndt Penteado, Marissa El-Hajje
{"title":"SETDB1: an emerging target for anticancer drug development.","authors":"Gustavo Henrique Goulart Trossini, Haifa Hassanie, André Berndt Penteado, Marissa El-Hajje","doi":"10.1080/17568919.2024.2444869","DOIUrl":"10.1080/17568919.2024.2444869","url":null,"abstract":"","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"153-155"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11749372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142885295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phthalimides as anti-inflammatory agents. 酞酰亚胺作为消炎剂。
IF 3.2 4区 医学
Future medicinal chemistry Pub Date : 2025-01-01 Epub Date: 2024-12-17 DOI: 10.1080/17568919.2024.2437979
Hector Mario Heras Martinez, Enrique Barragan, Kostiantyn O Marichev, David Chávez-Flores, Alejandro Bugarin
{"title":"Phthalimides as anti-inflammatory agents.","authors":"Hector Mario Heras Martinez, Enrique Barragan, Kostiantyn O Marichev, David Chávez-Flores, Alejandro Bugarin","doi":"10.1080/17568919.2024.2437979","DOIUrl":"10.1080/17568919.2024.2437979","url":null,"abstract":"<p><p>Isoindoline-1,3-dione, also referred as phthalimide, has gained recognition as promising pharmacophore due to the documented biological activities of its derivatives. Phthalimides are a family of synthetic molecules that exhibit notable bioactivity across various fields, particularly as anticancer and anti-inflammatory agents. This review focuses on syntheses and anti-inflammatory studies of the reported phthalimide derivatives. Although there are several synthetic protocols to produce phthalimide derivatives, two methods for synthesizing phthalimides are traditionally used: reacting phthalic anhydride with amines or anilines and the Gabriel synthesis. Due to their structural versatility and established pharmacological effects, derivatives of phthalimides such as the commercially available drugs thalidomide, pomalidomide, and lenalidomide, have driven the development of new derivatives offering hundreds of promising drug candidates with exceptional therapeutic potential, such as LASSBio 468 and adducts <b>2</b>, <b>9</b>, <b>150</b>, <b>241</b>, <b>255</b>, and <b>305</b> to name some.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":"17 1","pages":"125-142"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A short overview of dual targeting HDAC inhibitors. 双靶向HDAC抑制剂的简要概述。
IF 3.2 4区 医学
Future medicinal chemistry Pub Date : 2025-01-01 Epub Date: 2024-12-08 DOI: 10.1080/17568919.2024.2437975
Wen-Bo Liu, Jian Song, Sai-Yang Zhang
{"title":"A short overview of dual targeting HDAC inhibitors.","authors":"Wen-Bo Liu, Jian Song, Sai-Yang Zhang","doi":"10.1080/17568919.2024.2437975","DOIUrl":"10.1080/17568919.2024.2437975","url":null,"abstract":"","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"5-7"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prioritizing oral bioavailability in drug development strategies. 在药物开发策略中优先考虑口服生物利用度。
IF 3.2 4区 医学
Future medicinal chemistry Pub Date : 2025-01-01 Epub Date: 2024-12-26 DOI: 10.1080/17568919.2024.2444871
Lijuan Xie, Yingjing Hong, Yun Hu, Hongmei Li, Jie Lou, Xing Zhou
{"title":"Prioritizing oral bioavailability in drug development strategies.","authors":"Lijuan Xie, Yingjing Hong, Yun Hu, Hongmei Li, Jie Lou, Xing Zhou","doi":"10.1080/17568919.2024.2444871","DOIUrl":"10.1080/17568919.2024.2444871","url":null,"abstract":"","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"149-151"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11749343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biochemical evaluation of novel thiazolone derivatives as dual α-glucosidase/α-amylase inhibitors, anti-inflammatory agents. 新型噻唑酮类衍生物作为α-葡萄糖苷酶/α-淀粉酶双抑制剂、抗炎剂的生化评价。
IF 3.2 4区 医学
Future medicinal chemistry Pub Date : 2025-01-01 Epub Date: 2024-12-29 DOI: 10.1080/17568919.2024.2447225
Moustafa Salaheldin Abdelhamid, Salwa Samy Abdelfattah Eraky, Ibrahim Mohey El-Deen, Mohamed Ahmed Elian Sophy
{"title":"Biochemical evaluation of novel thiazolone derivatives as dual α-glucosidase/α-amylase inhibitors, anti-inflammatory agents.","authors":"Moustafa Salaheldin Abdelhamid, Salwa Samy Abdelfattah Eraky, Ibrahim Mohey El-Deen, Mohamed Ahmed Elian Sophy","doi":"10.1080/17568919.2024.2447225","DOIUrl":"10.1080/17568919.2024.2447225","url":null,"abstract":"<p><strong>Background: </strong>Using an analogue-based drug design approach, a number of novel 2-substituted-1,3-thiazolone derivatives (3-10) have been produced and given permission to proceed for their anti-inflammatory properties. In the present paper, the new thiazole derivatives were designed, synthesized, and tested for their alpha-glucosidase, alpha-amylase, and COX-inhibitory activities. Approving the anti-diabetic activity.</p><p><strong>Results: </strong>All the new derivatives were assessed in vitro compared to control (Acarbose) alpha-glucosidase, and alpha-amylase inhibition influence was showed shown through (3, 5, and 7) that were the most effective compounds as α-glucosidase inhibitors.</p><p><strong>Conclusions: </strong>Compounds (4 and 7) achieved the best effect as α-amylase inhibitors showed by IC<sub>50</sub> score near to that of control (Acarbose). Meanwhile, compound (4) exhibited a lower ferric-reducing anti-oxidant power (FRAP) value when compared to the control experiment (ascorbic acid). A molecular docking study approved the binding affinity and mode of binding of compounds (4 and 5) to the α-glucosidase and α-amylase binding pockets.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":"17 2","pages":"209-219"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11749350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143003293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信